Anxiety, It's Time to Go: New Book Ditches the Psychobabble to Remove Anxiety…for Good! 

Kevin Mullin’s ‘Anxiety, It’s Time to Go’ calls on the author’s vast experience as an NLP practitioner to help readers identify the root of their anxiety and not only remove it…but rid it for good. Using a series of proven techniques, this breakthrough guide could just be the most comprehensive and actionable self-help book on the market. One critic recently wrote, “It was all so simple, it made sense and it worked!!!”

Contact:

Kevin Mullin

Email: kevin@serenitynlp.com

Telephone: 07788119374

*Press Review Copies are Available from the Media Contact

*Kevin Mullin is Available for Interviews

FOR IMMEDIATE RELEASE

Ayr, Scotland – Those who suffer from anxiety and its related disorders understand it isn’t just disheartening, but an often-debilitating, life-destroying condition. And even worse, there’s a flood of books on the market conveying half-baked techniques that rarely actually work.

But that all now stops thanks to NLP practitioner Kevin Mullin and his new book, ‘Anxiety, It’s Time to Go’.

Just like the title, Mullins’ breakthrough text marks anxiety’s “grand finale” for its sufferers around the world, as they prepare to step into a new life free of the condition.

Synopsis:

Anxiety, It's Time to Go is not just another self-help book. It is 'the' self-help book. It uses cutting-edge tried and tested methods that have been used time and time again to remove anxiety from people each and every day. Anxiety, It's Time to Go will explain everything in simple terms and then show you exactly how to combat the things that hurt and control us when it comes to anxiety. The easy-to-follow exercise and instructions have been made straightforward without all the psychobabble that most people use. We say it as it is and then show you exactly how to remove it. This might just be the best thing you have done when it comes to beating crippling anxiety once and for all. 

“The over-riding goal with this book was to make it as straightforward and actionable as possible, with no fluff and no BS,” explains the author. “The fact of the matter is that anxiety is an epidemic in society these days and, unless someone steps in to do something about it, it’s going to continue destroying lives around the world.”

Continuing, “You need no prior understanding of NLP to use my book to change your life, and you also don’t need to fully understand your own anxiety. If you suffer, or even think you do, what I have to teach will radically improve your mental health and the overall quality of your life. Get a copy today!”

Reviews have been extremely positive. One reader writes, “I was given the book to read and I loved it. It was one of those books that I did not want to put down but equally did not want to finish, as I was enjoying it too much (like saving a new dress 'for best'). It was all so simple, it made sense and it worked!!! Now, I am not going to elaborate more, because I am now too busy living anxiety-free! Too busy enjoying life. Planning life. Too happy to even think about the old me who wasted so much time feeling anxious, stressed, miserable, not wanting to be here. So, read it for yourself.”

‘Anxiety, Its Time to Go’ is available now: https://amzn.to/2DvLkDQ. 

About the Author:

Kevin Mullin enlisted in the British Army aged fifteen years and eight months. He served in several conflict areas and operations around the globe, then at the age of thirty-four, he left the service and became a private military operator. Kevin was contracted to the United States Department of Defense, securing and protecting US Military bases and assets in Afghanistan. Kevin worked there for four years before moving to one of the most valuable targets in Afghanistan in the heart of Kabul – The Serena Hotel. Kevin studied NLP within the British Army and gained a wealth of knowledge and experience, training the trainers in the methods of approaches to NLP. Having suffered the loss of both his brother and mother, he was crippled with anxiety for many years. Kevin searched relentlessly for new, dynamic ways to beat it.

Having taken an apprenticeship with Ali Campbell, Kevin finally found what he was looking for. He understudied and role modelled Ali to great effect. In June 2017, Kevin opened his very own NLP practice based in Central Scotland. The practice has received rave reviews about Kevin’s new, dynamic and direct approach. He has helped thousands of clients become anxiety-free. Kevin has gained plaudits from Italy, Dubai and America for his dynamic and enthusiastic approach to motivational speaking and helping businesses and organisations flourish and grow. He is also a full-time parent. He raises his children with the approach he takes in life and in his crusade to help everyone in the battle with anxiety. Drive, determination and a vigour unparalleled in this modern age.

2019 Canada Gairdner Awards Recognize World-renowned Scientists for Transformative Contributions to Research that Impact Human Health

TORONTO, April 2, 2019 /CNW/ - On the 60^th anniversary of the Canada Gairdner Awards, the Gairdner Foundation is pleased to announce the 2019 Canada Gairdner Award laureates, recognizing some of the world's most significant biomedical research and discoveries. Laureates receive a $100,000 cash honorarium and are formally presented with their awards on October 24, 2019 at the annual Canada Gairdner Awards Gala in Toronto.

2019 Canada Gairdner International Award
The five 2019 Canada Gairdner International Award laureates are recognized for seminal discoveries or contributions to biomedical science: 

Dr. Susan Band Horwitz, Ph.D.
Distinguished Professor, Rose C. Falkenstein Chair in Cancer Research, Department of Molecular Pharmacology, Albert Einstein College of Medicine, New York

Awarded "For defining novel mechanisms of action and resistance of drugs of natural product origin, most significantly Taxol^®, and promoting their use for treatment of cancer"

The Work: Dr. Susan Band Horwitz is best known for elucidating the mechanism of action of Taxol®, a natural product obtained from the yew tree, Taxus brevifolia. Horwitz discovered that Taxol® binds to microtubules in cells, stabilizing them, thereby leading to cell cycle arrest and subsequent tumor cell death. This body of work enabled the successful translation of Taxol® into the clinic. It is one of the most frequently prescribed drugs in the world for the treatment of ovarian, breast and lung cancer. 

The Impact: Dr. Horwitz' research played a crucial role in encouraging the development of Taxol^® for use in the clinic. Although no one was interested in Taxol^®when she began her studies, today it is an important antitumor drug approved by the FDA for the treatment of ovarian, breast and lung carcinomas, as well as Kaposi's Sarcoma. The drug has been given to millions of cancer patients worldwide. Taxol^® also is used in the preparation of stents for cardiac disease. In addition, Taxol^® has proven to be an indispensable tool for scientists interested in microtubule structure, dynamics, and function. 

Dr. Ronald Vale, Ph.D. 
Professor, Cellular Molecular Pharmacology University of California, San Francisco; 
Investigator, Howard Hughes Medical Institute

Awarded "For the landmark discovery of the motor protein kinesin and pioneering the understanding of its mechanism of action in driving cellular movement processes including cell division and intracellular transport"

The Work: Vale's research has focused on molecular motor proteins, nature's nano-scale machines that convert chemical energy into directed movement. Vale began by asking how materials are transported in neurons, which are highly elongated cells that extend up to a meter in humans. Using squid as a model system, he developed a test-tube system to study this cellular transport process. This work led to the discovery of a new motility-producing molecule, which was named "kinesin". Vale's laboratory then uncovered the molecular choreography that enables this 1/millionth of an inch machine to drive movement. Collectively, Vale's work has informed, at a broad level, how living organisms generate motion.

The Impact: Dr. Vale's discovery of kinesin and molecular motors transformed the field of cell biology, placing a spotlight on the study of motor proteins. His research has illuminated the fundamental principles that underlie biological motility, an essential attribute of living organisms. The discovery of kinesin led to new tools for studying protein machines more broadly, sparked studies that connected motor proteins to innumerable cellular processes, and contributed to the realization that motility defects underlie various diseases of the nervous system, heart, and other organ systems.

Dr. Timothy A. Springer, Ph.D. 
Latham Family Professor of Biological Chemistry and Molecular Pharmacology, Professor of Medicine, Harvard Medical School and Boston Children's Hospital; Chairman, Institute for Protein Innovation

Awarded "For discovery of the first immune system adhesion molecules, elucidation of their roles in antigen recognition and leukocyte homing, and translation of these discoveries into therapeutics for autoimmune diseases"

The Work: Dr. Timothy Springer's work has changed understanding of cell-to-cell interactions that control immune responses and the movement of leukocyte subsets out of the vasculature into tissues. He discovered the first examples of cell recognition receptors and counter-receptors and the first family of integrins. He subsequently showed molecularly how integrins transmit signals between the exterior and interior of cells and enable cell movement. He opened the way for the first therapeutic use of antibodies to cell-cell recognition receptors to treat autoimmune diseases.

The Impact: Dr. Springer's discoveries and world-renowned work have transformed the fields of cell biology and immunology. His discoveries and entrepreneurship have led to an important new class of therapeutics for multiple autoimmune diseases including Psoriasis, Multiple Sclerosis, Ulcerative Colitis, Crohn's Disease and cancer.

Dr. Bruce Stillman, Ph.D., FRS
President, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York

Dr. John F.X. Diffley, Ph.D., FRS FMedSci
Associate Research Director, The Francis Crick Institute, London, U.K.

Awarded "For their pioneering research on the eukaryotic DNA replication cycles including initiation, regulation and responses to DNA damage"

Dr. Stillman:

The Work: Dr. Stillman's research focuses on how chromosomes, including both DNA and chromosome-associated proteins, are duplicated in human cells and in yeast, thereby ensuring accurate inheritance of genetic material from one generation to the next. Missteps in the process can lead to cancer. Dr. Stillman is most widely known for his groundbreaking discovery of the Origin Recognition Complex (ORC), the initiator protein complex that is universal among eukaryotes. His subsequent research determined how the initiation of chromosome replication occurs and how it is regulated. He also highlighted other functions of ORC proteins in cells, including controlling gene transcription and the duplication of centrosomes, structures that orchestrate chromosome separation during mitosis. Mutations in ORC have been linked to Meier–Gorlin syndrome, a condition that results in people with extreme dwarfism. 

Dr. Diffley: 

The Work: Our very large genomes must be accurately replicated in each cell cycle, no part of the genome should be replicated more than once and replication must be completed before cell division.  Using budding yeast as a model organism, Diffley has shown in molecular detail how DNA replication origins are regulated to ensure once per cell cycle replication. His laboratory has reconstituted the entire chromatin replication pathway using purified proteins.  This has led to an understanding of how the replicative DNA helicase is loaded at origins, how it is activated, how it nucleates assembly of the replication machinery and how the replication machinery displaces and re-deposits nucleosomes during replication. He has also shown that DNA damage checkpoints regulate DNA replication on damaged DNA templates by inhibiting replication origin firing and promoting replication fork stability.

The Impact: Each time a cell divides, it must copy its DNA equally into two new cells. If the cell's DNA is not copied precisely before it divides, new cells end up without necessary genetic information which can prevent their division, lead to cell death, or cause many cells to divide out of control, forming a tumour. 

By describing the exact sequence of events involved in DNA replication, Stillman and Diffley have provided key insights into how our genome is duplicated and how this process is coordinated with many other essential cellular events, which have implications for understanding genome instability and tumour heterogeneity in cancer. 

2019 John Dirks Canada Gairdner Global Health Award
The 2019 John Dirks Canada Gairdner Global Health Award laureate is recognized for outstanding achievements in global health research:

Dr. Vikram Patel, Ph.D., FMedSci
The Pershing Square Professor of Global Health and Wellcome Trust Principal Research Fellow, Department of Global Health and Social Medicine, Harvard Medical School; Professor, Harvard TH Chan School of Public Health; Honorary Professor of Global Mental Health, Centre for Global Mental Health, London School of Hygiene & Tropical Medicine; Adjunct Professor, Centre for Chronic Conditions and Injuries, Public Health Foundation of India, New Delhi; Co-founder, Sangath, India

Awarded "For his world-leading research in global mental health, generating knowledge on the burden and determinants of mental health problems in low- and middle-income countries and pioneering approaches for the prevention and treatment of mental health in low-resource settings"

The Work: Dr. Patel has dedicated his research career to raising the global profile of mental health problems through: epidemiological research demonstrating the burden of mental disorders in low- and middle-income countries, their strong association with poverty and with other public health priorities, such as HIV and child growth and development; and intervention research in which he has applied a systematic approach to the design, delivery and evaluation of contextually appropriate psychosocial interventions provided by lay and community health providers. This has included the primary care treatment of depression, anxiety and alcohol use disorders, the community-based care of people with schizophrenia and autism, and the prevention and treatment of adolescent mental health problems through school-based interventions. 

Much of his work has been done in partnership with Sangath, an Indian NGO he co-founded in 1996. Sangath is one of India's leading community-based research organizations which won the MacArthur Foundation International Prize for Creative & Effective Institutions in 2008 and the WHO Public Health Champion of India prize in 2016. Dr. Patel also co-founded the Centre for Global Mental Health and the Mental Health Innovations Network (at the London School of Hygiene & Tropical Medicine) and the Movement for Global Mental Health, the largest global network of individuals and organizations advocating for promoting services and human rights for people living with mental health problems. In 2018, he co-founded the GlobalMentalHealth@Harvard initiative which is developing a suite of innovative, inter-disciplinary, initiatives aimed at implementing and generating knowledge to transform mental health globally. 

The Impact: As recently as 10 years ago, it was difficult to even imagine mental health problems being considered as a global health priority; today, the situation is radically different with considerable attention from a diverse range of global health stakeholders, backed by resources, being focused on mental health, particularly in disadvantaged and low resourced contexts. Patel's work and leadership has played a critical role in making this happen. His research has challenged many of the myths surrounding mental health problems in the global context, demonstrating that these problems are universal forms of human suffering; that there is a vicious cycle of deprivation and poor mental health; that mental health problems profoundly affect the physical health and well-being of affected persons; that psychosocial interventions can be effectively delivered by widely available and affordable community based providers; and that the human rights of people with mental health problems to access quality care and to a life with dignity are global concerns. This work and his leadership has made significant contributions to the establishment of the field of global mental health, with priority research, teaching, policy and practice agendas, for example the Grand Challenges in Global Mental Health research initiative, the World Health Organization's flagship mhGAP program on mental health and India's first national mental health policy. 

2019 Canada Gairdner Wightman Award
The 2019 Canada Gairdner Wightman Award laureate is a Canadian scientist recognized for outstanding leadership in medicine and medical science throughout their career: 

Dr. Connie Jean Eaves, Ph.D. 
Distinguished Scientist, Terry Fox Laboratory, BC Cancer; Professor, Department of Medical Genetics, University of British Columbia, Vancouver, BC 

Awarded "For her pioneering work and leadership in the study of hematopoietic, mammary and cancer stem cells and her dedicated advocacy for early- career investigators and women in science"

The Work: Dr. Eaves' research has focused on leukemia and breast cancer and the normal tissues in which these diseases originate. Eaves together with her husband, Allen Eaves, and a dedicated group of talented trainees developed methodologies to isolate putative stem cells from living mouse and human tissues, and detect them based on their ability to grow as single cells in specialized tissue cultures or in transplanted mice. This made it possible to quantify blood and mammary gland stem cells in different situations, and discover a hidden population of suppressed normal blood stem cells in patients with leukemia, which has stimulated a search for new therapies. Eaves also showed that leukemic stem cells are actually not dividing most of the time. Her studies of breast cells revealed that similar principles apply to understanding the normal growth of this tissue. More recently, she has developed new methods for creating human leukemia and breast cancer experimentally. 

Throughout her distinguished career, Dr. Eaves has demonstrated outstanding national and international leadership. She co-founded the Terry Fox Laboratory at the British Columbia Cancer Agency, was a leader in the Canadian Stem Cell Network and held multiple senior roles in the National Cancer Institute of Canada, where she spearheaded the establishment of the Canadian Breast Cancer Research Alliance to create the first national source of breast cancer research funding in Canada.  

In addition to the national and international accolades received throughout her career, Dr. Eaves is recognized for her exceptional commitment to the training of more than 100 scientists from around the world, including many now in senior leadership positions. Dr. Eaves is also a passionate advocate for the advancement of women in science, a commitment that led to her recognition as a Status of Women Canada Pioneer. 

The Impact: Dr. Eaves has shown great initiative and immense talent across her five-decade career. Her dedication to multidisciplinary research and to providing the best training possible for aspiring researchers has strengthened Canadian science and garnered international recognition. 

Eaves' scientific findings have been paradigm-shifting, driving the field of stem cell research forward. Her provision of reproducible and rigorously quantitative methods for analysing the rare cells responsible for maintaining normal blood and mammary tissues has enabled many new lines of research. Eaves continues to apply cutting-edge technology and elegant experimental design to the most pertinent problems in stem cell biology and cancer research, constantly contributing to the ongoing pursuit of cures. 

QUOTES: 

"On the 60^th anniversary of the Canada Gairdner Awards, the Gairdner Foundation continues to uphold the tradition of honouring the best and brightest researchers from around the world. Whether it is the field of global mental health, stem cell biology or fundamental cell biology and DNA replication, the work of each of this year's laureates is both critical and extraordinary," said Dr. Lorne Tyrrell, Chair, Board of Directors, Gairdner Foundation. 

"2019 is an exciting year for the Gairdner Foundation. On the 60^th anniversary of the awards, Gairdner is proud to recognize another outstanding group of laureates. This fall, each of the 2019 Canada Gairdner Award laureates will participate in outreach programs across Canada to share their research and passion for science with graduate students, trainees, post-docs, faculty members and high school students," said Dr. Janet Rossant, President & Scientific Director, Gairdner Foundation.  "I have no doubt that our 2019 laureates will help us to inspire the generation of scientists and researchers, and continue to raise the calibre of scientific conversation across the country." 

About the Canada Gairdner Awards:

Each year seven Canada Gairdner Awards are presented to honour the world's most significant biomedical and global health researchers. The Canada Gairdner International Award is given to five individuals for outstanding international biomedical research, while the Canada Gairdner Wightman Award is given to an individual leader in Canadian medicine. The John Dirks Canada Gairdner Global Health Award recognizes a contribution to health in the developing world. These seven awards both distinguish Canada as a leader in science and elevate the profile of science in Canada. They are Canada's only globally known and respected international science awards. All laureates are chosen by international adjudication committees. 

About the Gairdner Foundation:

The Gairdner Foundation was established in 1957 by Toronto stockbroker, James Gairdner to award annual prizes to scientists whose discoveries have had major impact on scientific progress and on human health. Since 1959 when the first awards were granted, 380 scientists have received a Canada Gairdner Award and 89 to date have gone on to receive the Nobel Prize.The Canada Gairdner Awards promote a stronger culture of research and innovation across the country through our Outreach Programs including lectures and research symposia. The programs bring current and past laureates to a minimum of 15 universities across Canada to speak with faculty, trainees and high school students to inspire the next generation of researchers. Annual research symposia and public lectures are organized across Canada to provide Canadians access to leading science through Gairdner's convening power.

SOURCE Gairdner Foundation

peopleCare Wins Innovation of the Year Award for the First Clinical Pharmacy Model in Canadian Long-Term Care

WATERLOO, ON, April 2, 2019 /CNW/ - With the complexity of care needs on the rise for Ontario's 68,000 long-term care residents, the need for an innovative approach to better manage their medications has never been more crucial. That's why peopleCare Communities and its partners developed a ground-breaking clinical pharmacy model, which has won a Quality Improvement Innovation Award from the Ontario Long Term Care Association (OLTCA).

"We are thrilled to receive this recognition from the long-term care sector for our leading practice Clinical Pharmacy Model," says Megan Allen-Lamb, President of peopleCare Communities. "The Award is an outstanding validation of our commitment to collaboratively drive innovation in the health system that directly improves the safety and quality of the care we provide to our residents."

A first of its kind in the Canadian long-term care environment, peopleCare's Clinical Pharmacy Model connects pharmacists directly with residents and staff, and leverages best-in-class software and automated dispensing cabinets. Research shows having an on-call pharmacist leading the medication reconciliation process supports higher quality decision-making and often results in fewer residents taking unnecessary medications, which is safer and more cost-effective. 

The tele-pharmacy component of the model ensures expert medication reconciliation is available at any time, with full remote access to the electronic health record and medication lists. More efficient, this also enhances communication among the care team, particularly during transitions, when residents are more vulnerable to medication errors.

peopleCare and its partners – including Hogan Pharmacy Partners, eHealth Ontario, the LTC eConnect program, and PointClickCare – developed and piloted the Clinical Pharmacy Model in peopleCare's long-term care homes with the help of a $500,000 grant from the Ontario Healthcare Technologies Fund – the largest ever single grant awarded by the program. 

Data from the pilot phase demonstrates the model's effectiveness at improving resident safety and supporting better clinical outcomes. Medication reconciliation improved by 43%. Staff documented a dramatic 8-hour decrease in the average time to first dose for residents newly admitted or re-admitted after a hospitalization. The new approach also freed up hundreds of hours of staff time that could be redirected to resident care.

According to Jenn Killing, peopleCare's Vice President of Quality and Innovation, over the past year peopleCare has worked proactively to share this trailblazing model with government, sector partners and experts, and plans to keep engaging with interested organizations in the coming months. 

"All long-term care residents in Ontario would benefit significantly from this innovative solution," says Jenn. "We strongly encourage our health sector colleagues to connect with us to learn more about how they can leverage our Clinical Pharmacy Model to provide safer, more effective care for their residents. Our process, tools and lessons learned are an open book."

The OLTCA Quality Improvement Innovation of the Year Award is presented for a change idea, research project or collaboration with health care stakeholders, having achieved a positive impact on residents, staff or the home in early results.  peopleCare's Clinical Pharmacy Model "Innovation of the Year" is showcased in the Spring/Summer 2019 issue of OLTCA's LONG-TERM CARE TODAY. 

About peopleCare CommunitiespeopleCare Communities is a leading operator of senior living communities in southwestern Ontario, with strong family values and a long history of service. We are committed to creating vibrant communities of care that deliver clinical best practices, engaging programs and integrated services that meet seniors' changing needs. peopleCare's innovation and industry leadership has earned Accreditation Canada – Exemplary Status, Canada's Best Managed Companies designation for the sixth straight year, North America's Most Engaged Workplaces Award, and an Innovation Award research grant from the Health Technology Fund. 

Related links: www.peoplecare.ca

SOURCE peopleCare Communities

Post-Traumatic Stress Disorder: Some Questions and Answers

Q: What is Post-Traumatic Stress Disorder or PTSD?

A: Weeks, months, or years after a traumatic event, survivors can find themselves bombarded with flashbacks, feelings of fear, sadness or anger and strong reactions to triggers such as loud noises. Post-traumatic stress disorder, also known as PTSD, is a mental health condition that can be helped with appropriate care. 

Q: What can trigger PTSD?

A: Disturbing or catastrophic events such as natural disasters, car accidents, terrorist attacks, shootings or other physical attacks, rape, war or the death of a loved one could lead to PTSD. Those who experience PTSD could themselves be a victim of a traumatic event or witnesses to others’ suffering, either directly, by seeing injuries, or indirectly, as in the case of those who learn of details of attacks or abuse. 

Q: Who develops PTSD?

A: Not everyone who is exposed to trauma develops PTSD. The symptoms are more common in women and those who experienced previous trauma, particularly as children. PTSD is also more prevalent in those with other physical and mental health conditions. 

Q: When does PTSD arise?

A: Everyone feels shaken immediately after a traumatic event.  However, for people with PTSD, symptoms persist more than a month after the event and continue for months or years. For some people, PTSD symptoms do not appear until several months after the event. 

Q: What are the symptoms of PTSD?

A: Symptoms include involuntary memories or vivid flashbacks of the traumatic event and disturbing dreams. People with PTSD may experience feelings of anger, guilt and shame. They may no longer find pleasure in their favorite activities. Some feel isolated, drawing away from family and friends. They may avoid triggers that remind them of the distressing event, including places, objects, people or activities. People with PTSD may feel irritable, engage in self-destructive behaviors, have problems concentrating or sleeping, respond strongly to loud noises or unexpected touches, or have angry outbursts. Some have physical symptoms, including increased heart and blood pressure rates, unexplained pain and fatigue. 

Q: How can PTSD be treated?

A:There is help for PTSD. It can be treated. Proven treatments include cognitive behavioral therapy, cognitive processing therapy, eye movement desensitization and reprocessing (EMDR) and Accelerated Resolution Therapy (ART). Some people may also find relief with medications, such as antidepressants, as well as therapy. 

Q: What is Accelerated Resolution Therapy (ART)?

A: ART is a therapeutic technique performed by a therapist, social worker or counselor who has undergone specialized training. The practitioner guides a client’s eyes through a series of lateral movements while talking through a series of prompts. The technique empowers clients to move traumatic memories out of the forefront of the brain. Clients are able to reframe troubling experiences. ART was created more than a decade ago and has been proven effective in numerous scientific studies, including several conducted by the Department of Defense. Most clients experience a complete or significant reduction of their symptoms in an average of four sessions with ART. Clients do not need to discuss the details of their disturbing experience with the clinician who is treating them, making ART an effective treatment for those who do not feel comfortable discussing the traumatic event. Many clients try ART after other treatments fail and find that the therapeutic technique finally enables them to heal from the trauma. For more information about ART, please visit artherapyinternational.com. 

Interviews can be arranged with Kelly Breeding, LCSW, the executive director of ART International, therapists who employ ART in their practices, and Kevin Kip, Ph.D, a trauma expert who has conducted significant research into the efficacy of ART. Several former clients who found relief with ART are also available for interviews, including Brian Anderson, a former Green Beret who developed PTSD from combat-related trauma.  Contact Julie Scharper, jscharper@hillmanpr.com, to schedule interviews. 

To Coincide with the Boston Marathon, 

Safety Wearable Technology Company, Run Angel, 

Announces New Charity Partnership with Angel Flight Northeast

BOSTON – APRIL 1, 2019– Safety wearable technology company, Run Angel Ltd. , today announced it has partnered with Angel Flight Northeast, a non-profit organization that coordinates free air transportation for patients to access life-saving medical care.

"Angel Flight Northeast is a story of courageous men, women and children who have an incredible will to live. Partnering with Angel Flight Northeast in advance of the one of the greatest running events of the year, the Boston Marathon, was an obvious choice for us," said Ellen Caren, Founder of Run Angel. "We at Run Angel, share in Angel Flight Northeast’s commitment and dedication in helping those most in need, especially in an emergency situation.”

Run Angel™ is an innovative safety wrist wearable that emits a very loud siren from its patent pending acoustic chamber design to attract attention in an emergency and connects with smartphone devices to send emergency alerts to loved ones by SMS & email, showing the date, time and location of the wearer. 

“We are honored and humbled that Run Angel has chosen Angel Flight NE as their charity of choice with a percentage of the proceeds from their Limited-Edition Boston Angel, inspired in the colors of the renowned Boston Marathon, going to support our mission,” said Larry Camerlin, President and Founder of Angel Flight Northeast. “Much like our mission to make a profound difference in the lives of our patients and their families, Run Angel‘s personal safety wearable makes a difference in the lives of those who wear it as well as in the lives of those they care about and love.”

Angel Flight Northeast is a non-profit that coordinates free air transportation services for patients who need to travel outside of their area for specialized medical care. This is made possible with the volunteer corps of over 500 private pilots who combine their love of flying with the spirit of grassroots volunteerism by flying patients and their families to the critical health care they need along with the assistance of commercial aviation partners. Founded in 1996, AFNE have scheduled over 77,000 flight requests and have flown more than 15 million miles.

For more information regarding Angel Flight Northeast, please visit www.angelflightne.org/

A blue and yellow Limited Edition ‘Boston Angel’ is now available from www.runangel.com at $80. For more information please contact: Ellen Caren on 001 (646) 844-3866 or by email at ellen@runangel.com

“Run Angel demonstrates the importance of staying safe while staying active,” said Catie Riordan, VP of Consumer Retail, Enterprise Ireland. “We are so proud to support Run Angel and it is so fantastic to see them teaming up with Angel Flight NE for a meaningful and worthwhile partnership.”

About Enterprise Ireland

Enterprise Ireland is the Irish State agency that works with Irish enterprises to help them start, grow, innovate and win export sales in global markets. Enterprise Ireland partners with entrepreneurs, Irish businesses, and the research and investment communities to develop Ireland's international trade, innovation, leadership, and competitiveness.  In this way, we support sustainable economic growth and regional development and help create and sustain employment in Ireland.

IMAGES FOR USE:

The World's First Affordable At-home Live Cell Collection Kit Now Available, Readying Everyone for the Future of Cell Therapy & Genetics

In-person collection experience debuts at MaRS Health Innovation Week; pre-order now open for innovative live cell home collection kit in Canada.

TORONTO, April 1, 2019 /CNW/ - Acorn Biolabs, a healthcare technology company focused on giving every human being the best chance to enjoy greater health as they age, has launched the world's first easy and affordable live cell collection, genetic analysis, and cryopreservation service through its non-invasive method of simply plucking a few hairs from your head.

With an introductory one-time collection fee of $299, Acorn will collect and cryopreserve your cells for future medical use. The one-time fee will include collection, a cell viability report, cell images, a report outlining your genetic age, as well as storage of your cells for your first year with Acorn. Annual cell storage fees as low as $99 for children under the age of 19 years old will be billed to clients who sign up for the service starting in their second year.  Acorn is also making available a client referral program.

"Cell therapy is rapidly emerging as the future of healthcare," said Dr. Drew Taylor, Co-founder and CEO at Acorn Biolabs. "Your own cells are the key to leveraging its potential, increasingly unlocking preventative healthcare that can improve your healthspan. Medical advancements have allowed for doctors to use your own cells to predict, treat, and even eradicate disease and degenerative changes. Stem cell therapies, tissue engineering strategies, and regenerative medicine are all powered by using cells."

As cells age, they become increasingly damaged and less effective for use with cell therapy treatments. That's why consumers have already started to collect, preserve and store their cells as soon as possible — locking in their cells at their best.  Unfortunately, existing methods of collecting live cells are highly invasive: from bone marrow extractions to liposuction surgery, and from venous blood draws to tissue harvesting. These procedures are painful and require medical teams, making live cell collection widely out of reach for most people.  

To demonstrate how easy and accessible live cell collection can be, Acorn will debut its in-person live cell collection experience at a series of events across Canada this year including: MaRS Health Innovation Week, Total Health '19, Technology & The Future Of Healthcare 2019, Collision, BigData Toronto and Elevate, among others.  At these events, consumers can personally experience Acorn's easy, non-invasive live cell collection service by having their own cells collected on-site.

Also starting today, Acorn has started taking pre-orders for its at-home live cell collection kit which is due to ship this year. The innovative kit design, supported by Acorn's non-invasive method, will allow consumers to collect their own live cells easily and non-invasively in the comfort of their homes by plucking their own hair follicles. Consumers can hold their place in line for the first run of kits by pre-ordering today at www.acorn.me.

Acorn demonstrated their unique capability today on stage at MaRS Health Innovation Week with a hair follicle collection demo where they plucked hairs of attendees in front of a live audience - safely collecting their cells for future medical use.  

Today's popular saliva-based DNA home-collection kits are low cost cell collection alternatives, but only capture dead human cells, limiting their use. These DNA and ancestry tests currently focus on less than 1% of a full genome making it impossible to leverage those cells for anything other than ancestry and basic health reports. 

Acorn's non-invasive method of plucking hair on your head allows for full genome collection, in addition to banking your live cells - all without traveling to a clinic or needing a physician or surgery, making live cell collection significantly more affordable and accessible for everyone.

Easily accessible, progressively more powerful.  Your own cells are the next currency in healthcare.

About Acorn Biolabs, Inc.
Founded in 2017 by Steven ten Holder, Patrick Pumputis and Dr. Drew Taylor and born out of years of research, Acorn is a healthcare technology company.   Based at Johnson & Johnson INNOVATION -  JLABS in Toronto, in the MaRS Discovery District – the heart of innovation in medicine and biotechnology -  Acorn is focused on giving every human being the best chance to experience more healthy years with its easy, affordable and non-invasive live cell collection, analysis and cryopreservation service. Acorn helps you save your cells today, to live a longer, healthier tomorrow. Visit acorn.me

SOURCE Acorn Biolabs

If you would rather not receive future communications from TOTAL Public Relations, let us know by clicking here.
TOTAL Public Relations, PH17-135 Village Green Square, Toronto, Ontario M1S 0G4 Canada

Blume, The Female Founded Self-care Company Focused on Empowering Girls, Raises $3.3 Million in Series Seed Funding 

Capital from the round will be used to expand product offerings, grow the team, and create more educational contentVANCOUVER, BC - April 1, 2019 - Blume,the only brand dedicated to educating young women and creating safe and sustainable period products, announced a $3.3 million Series Seed funding round today. The round is led by Grace Chou and Victoria Treyger, partners at Felicis Ventures, with participation from Victress Capital. Other notable investor participants include Panache & Eric Reis, author of the Lean Startup. Sisters and co-founders Taran and Bunny Ghatrora, first generation women from Indian descent, are committed to empowering young women. The entrepreneurial duo, both 500 Startups Fellows, hope to instill self-acceptance and confidence in a new generation of young women through a combination of safe products and educational content.  It's clear that the current puberty and self-care options on the market aren't cutting it and with this funding, Blume is able to continue to give women and girls the tools they need to grow into the best version of themselves. Capital from this round will be used to accelerate brand growth through product and employee expansion and increased marketing efforts to produce more educational content. The funding signifies the importance of the brand's mission to empower young women. Round leader, Victoria Treyger, General Partner and Managing Director at Felicis Ventures, is thrilled to lead Blume's seed round and support Blume's mission of re-imagining puberty and personal care for GenZs. "We are impressed by Blume's holistic approach to transforming the category - starting from an expanding line of wellness products, to authentic educational content on physical and mental health, as well as innovative omnichannel concepts that resonate with teens. Moreover, how Blume taps into its loyal community to co-create new products is something incumbent CPG brands cannot do themselves," said Treyger. Suzanne Norris, partner at Victress Capital felt there was a noticeable white space in the $15B personal care market for products that were made for and specifically marketed to Gen Z girls. "Blume is the only brand that is approaching the Gen Z consumers' needs in this cohesive way across both commerce and content, and we believe they will develop the next generation of confident, tenacious and conscious women.  We strongly support Blume's mission and we are honored to partner with their team," said Norris. Taran & Bunny Ghatrora, co-founders of Blume, are excited to use this new funding to continue to build the brand girls grow up with and the supportive community that will help create next generation of thriving, confident and tenacious young women. "We plan to double down on building community and our educational platform. With only 26 States mandating sex ed, and Ontario, Canada reverting back to a pre-1993 sex ed curriculum, we believe there is space for a brand to help girls navigate this time in a meaningful way, with accurate, factual content presented in a voice and tone that is non clinical," said Taran Ghatrora, co-founder and CEO. At a time where less than 2.2% of venture capital goes to women, and even less to women of color, Blume is thankful to build this company with strong partners, and are committed to having a diverse board as the brand continues to grow. "We're honored to be working alongside amazing investors, many of whom, are parents of teens themselves and be part of the journey of the thousands of parents who have told us that their daughters are feeling more confident and opening up to them in ways they never have!" said Bunny Ghatrora, Co-Founder and COO.
You can view brand imagery HERE. 
PRESS CONTACT:Nicole ClarkMichele Marie PRNicole@michelemariepr.com646.863.3923
About Blume:Blume is building young women a safe space to learn, grow, and become their badass selves. A place to celebrate womanhood and give advice on the good, the bad and, yes, even the ugly that comes with it. We provide dependable, high-quality, beautiful content, education, and safe products for your period and just life in general. Most brands carry period products that take centuries to biodegrade and have ingredients you can't pronounce. At Blume, we're different. We believe in products that are not a threat to our bodies or the environment. We offer a subscription box at just $11 a month and a wide range of life products such as organic tampons and pads, fun treats, and comforting remedies for everything PMS. Individual products retail from $11 - $26 and are available at select Nordstrom and Urban Outfitter locations and on www.meetblume.com.

Beyond Legalization: 2nd Medical Cannabis Week highlights importance of continued R&D in the industry

Business of Cannabis Announces Initial Programming and Launch of Medical Cannabis Talks Series to Focus Medical Cannabis Conversation

TORONTO, April 1, 2019 /CNW/ - Business of Cannabis announces that Canada's second annual Medical Cannabis Week will take place from May 6 to May 10, 2019 with programming running in Toronto as well as in other locations across the country.

"Understanding the foundational role that medical cannabis brings to the sector, we wanted to grow the platform across which this conversation will be hosted," said Jay Rosenthal, Co-Founder and President of Business of Cannabis, "This year we are announcing extended programming and a new content series to aggregate and focus on conversations related to the research, innovation, advocacy and regulatory issues."

Current speakers includes leaders from Ample Organics, Blake, Cassels & Graydon LLP, HelloMD, Jamaican Medical Cannabis Corporation, Medicinal My Way, Opportunities New Brunswick and Strainprint Technologies, with more participants and venues to be announced in the coming weeks. The National Post is the official media partner for the week.

Events will kick off with a new content format: Medical Cannabis Talks which will see industry leaders present their impressions on the sector via live stream, as well as being aggregated into a new platform managed by Business of Cannabis.

"One of our key objectives in launching Medical Cannabis Week was to provide a dedicated space to focus on the conversations most important to the medical cannabis sector," said Blaine Pearson, Co-Founder and CEO, Business of Cannabis. "Medical Cannabis Talks will ensure that we continue to shine a light on the important advances in the medical cannabis space all year round."

To learn more about Medical Cannabis Week and to RSVP to specific events, please visit medicalcannabisweek.com.  

About Business of Cannabis
Business of Cannabis is a leading cannabis business media platform connecting industry leaders and investors with business news, specialized event programming and strategic consulting. With the objective of helping the cannabis sector reach maturity faster, Business of Cannabis produces sophisticated digital content, niche events series and creative programs for B2B and B2C audiences. Founded in 2017, Business of Cannabis has earned its place as a respected and trusted voice for the industry and investors in the ever-expanding international cannabis space. For more information, please visit www.businessofcannabis.ca

SOURCE Business of Cannabis